AIG Hospitals in Hyderabad has inaugurated a dedicated Gut Microbiome Therapeutics and Pill Lab with an initial focus on inflammatory bowel disease (IBD). The facility will develop oral microbiome capsules using rigorously screened donor material for clinical research.

  • AIG Hospitals launches a dedicated Gut Microbiome Therapeutics and Pill Lab.
  • Research will initially target inflammatory bowel disease, including ulcerative colitis and Crohn's disease.
  • All stages—from donor screening to capsule formulation—will follow strict quality and safety protocols.

On Saturday, August 29, AIG Hospitals in Hyderabad unveiled a state‑of‑the‑art Gut Microbiome Therapeutics and Pill Lab. The laboratory is designed to explore the therapeutic potential of the human gut microbiome, with a primary emphasis on inflammatory bowel disease (IBD).

The core mission is to create oral microbiome capsule formulations derived from scientifically screened donor material. The workflow includes microbiome profiling, controlled sample processing, preservation, capsule formulation, rigorous quality and safety checks, and adherence to clinical research protocols.

Read Also:Breakfast or Dinner: Determining the Optimal Time for Protein Consumption

D. Nageshwar Reddy, Chairman of AIG Hospitals, highlighted that restoring a healthier microbial ecosystem could unlock significant benefits for chronic inflammatory conditions where conventional therapies often fall short.

Rupa Banerjee, Director of the IBD Centre, emphasized that the facility prioritizes scientific quality, donor safety, standardized processes, traceability, and clinical relevance. “Every step, from donor screening to capsule formulation and patient monitoring, will be conducted under defined protocols,” she said.

The gut microbiome—trillions of microorganisms residing in the digestive tract—plays a crucial role in immunity, inflammation, metabolism, gut‑barrier function, and treatment response. Dysbiosis, or microbial imbalance, has been linked to a range of gastrointestinal and systemic diseases, especially IBD.

Why This Matters

BozokMedia analysis shows that microbiome‑based therapeutics are still emerging in India, yet they hold transformative potential for global healthcare. This lab not only strengthens local research capabilities but also creates a platform for international collaborations and clinical trials.

“Therapies targeting the microbiome could fundamentally change how we treat complex diseases like IBD,” noted a leading gut microbiome expert.
Did You Know?: The number of bacterial cells in the gut microbiome outnumbers human cells in the body by roughly ten to one.

Frequently Asked Questions

Q1: Will the microbiome capsules be available to the public soon?
A: No, they are currently intended solely for use within approved clinical research programs.

Q2: How is donor material safety ensured?
A: Donor screening involves comprehensive health assessments, microbiome profiling, and strict quality‑control standards.